Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer

Expert Opin Investig Drugs. 2017 Feb;26(2):133-136. doi: 10.1080/13543784.2017.1274392. Epub 2016 Dec 27.

Tarkan Jäger¹, Matthias Ocker^{2

3}, Tobias Kiesslich^{4

5}, Elen Neureiter⁶, Daniel Neureiter^{7

8}

¹ a Department of Surgery , Paracelsus Medical University, Salzburger Landeskliniken (SALK) , Salzburg , Austria.
² b Experimental Medicine Oncology , Bayer Pharma AG , Berlin , Germany.
³ c Department of Gastroenterology CBF , Charité University Medicine Berlin , Berlin , Germany.
⁴ d Department of Internal Medicine I , Paracelsus Medical University, Salzburger Landeskliniken (SALK) , Salzburg , Austria.
⁵ e Laboratory for Tumour Biology and Experimental Therapies (TREAT) , Institute of Physiology and Pathophysiology, Paracelsus Medical University , Salzburg , Austria.
⁶ f Faculty of Chemistry , University of Vienna , Vienna , Austria.
⁷ g Institute of Pathology , Paracelsus Medical University, Salzburger Landeskliniken (SALK) , Salzburg , Austria.
⁸ h Cancer Cluster Salzburg (CCS) , Salzburg , Austria.

No abstract available

Keywords: Hedgehog pathway; drug development; inhibitors.

Publication types